SPY304.32+1.35 0.45%
DIA254.29-0.06 -0.02%
IXIC9,489.87+120.88 1.29%

Recap: Athenex Q1 Earnings

Shares of Athenex (NASDAQ:ATNX) fell 4.8% after the company reported Q1 results. Quarterly Results Earnings per share were up 54.72% year over year to ($0.24), which missed the estimate of ($0.17). Revenue of $46,935,000 up by 85.46% year over year, which beat

Benzinga · 05/07/2020 13:47

Shares of Athenex (NASDAQ:ATNX) fell 4.8% after the company reported Q1 results.

Quarterly Results

Earnings per share were up 54.72% year over year to ($0.24), which missed the estimate of ($0.17).

Revenue of $46,935,000 up by 85.46% year over year, which beat the estimate of $32,860,000.

Guidance

Athenex hasn't issued any earnings guidance for the time being.

Revenue guidance hasn't been issued by the company for now.

Conference Call Details

Date: May 07, 2020

Time: 09:00 AM ET

Webcast URL: http://public.viavid.com/player/index.php?id=139326

Recent Stock Performance

52-week high: $21.11

52-week low: $5.63

Price action over last quarter: down 20.87%

Company Overview

Athenex Inc is a global biopharmaceutical company. It is dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer. The company's operating segment includes the Oncology Innovation Platform; Global Supply Chain Platform and Commercial Platform. It generates maximum revenue from the Commercial Platform segment. Commercial Platform segment includes APD, which focuses on the manufacturing, distribution, and sales of specialty pharmaceuticals. Geographically, it derives a majority of revenue from the United States and also has a presence in Spain; Austria; India; China; the United Kingdom and Other foreign countries.